Unicycive Therapeutics Inc(UNCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:59 PM ET (Korea 10/31 08:59)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.6 | Insider Own | 4.24% | Shs Outstand | 27.9M | Perf Week | -3.86% |
| Market Cap | 0.10B | Forward P/E | 2.66 | EPS next Y | 212.94% | Insider Trans | - | Shs Float | 26.7M | Perf Month | -17.8% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.35 | Inst Own | 45.34% | Short Float | 18.29% | Perf Quarter | -26.01% |
| Income | -0.04B | P/S | - | EPS this Y | 25.33% | Inst Trans | 5.07% | Short Ratio | 5.49 | Perf Half Y | -51.24% |
| Sales | 0.00B | P/B | 1.96 | EPS next 5Y | - | ROA | -69.05% | Short Interest | 4.88M | Perf YTD | -35.18% |
| Book/sh | 1.91 | P/C | 1.7 | EPS past 3/5Y | 48.15% -2.4% | ROE | -101.07% | 52W High | -57.21% ($8.74) | Perf Year | -22.25% |
| Cash/sh | 2.2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -66.06% | 52W Low | 11.64% ($3.35) | Perf 3Y | -38.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.63% | Gross Margin | - | Volatility(W/M) | 6.84% 6.5% | Perf 5Y | -87.06% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | EPS Q/Q | 87.79% | Profit Margin | - | RSI (14) | 40.45 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.81 | Sales Q/Q | - | SMA20 | -2.5% ($3.84) | Beta | 1.87 | Target Price | $29.56 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/12 | SMA50 | -17.59% ($4.54) | Rel Volume | 1.46 | Prev Close | $3.81 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 87.26% - | SMA200 | -38.71% ($6.1) | Avg Volume(3M) | 0.89M | Price | $3.74 |
| IPO | 2021/7/13 | Option/Short | Yes/Yes | Trades | 5139 | Volume | 1,300,302 | Change | -1.84% |
A US clinical-stage biotech company developing new drugs in the chronic kidney disease space. Its lead candidate is oxylanthanum carbonate, a treatment for hyperphosphatemia in dialysis patients. Headquartered in the U.S., the company operates a pipeline targeting the unmet needs of the kidney disease market.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded more than usual. That is 146% of its average volume.
UNCY has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 45.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #350 of 597 in the industry
Based on market cap of $104M.
VYGR#349 Voyager Therapeutics Inc $106M PER - UNCY#350 Unicycive Therapeutics Inc $104M PER - 
TLSA#351 Tiziana Life Sciences Ltd $103M PER - 
ENGN#352 enGene Therapeutics Inc $103M PER - 
IMUX#353 Immunic Inc $102M PER - 
FAQ
What kind of company is UNCY?
UNCY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of UNCY?
The market cap of UNCY is approximately $104M, ranking 4,436 within its sector.
What is the 52-week high and low for UNCY?
UNCY has recorded a 52-week high of $8.74 and a low of $3.35.
